A collaboration between a New Zealand biotech and the US Army aims to advance the development of lab-grown skin replacements for burns victims.
Upside Biotechnologies and the US Army Medical Research and Materiel Command (USAMRMC) this week signed an R&D deal to promote Upside’s pioneering skin replacement treatment.
Upside CEO Dr Robert Feldman said: “This US Army input will be hugely valuable to Upside and will fully assist us in successfully progressing our product to the benefit of all burn sufferers, including US warriors.”
The USAMRMC wants to help in fast-tracking its progress for use by American services.
Susan Taylor, product manager at USAMRMC, added: “This product may provide a critical solution in the treatment of service members who have sustained severe burns. Our goal is to help Upside move this product as quickly and as safely as possible through the regulatory process, so it is available to our wounded service members.”
